Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | GCGR | P47871 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829472 | 1.00 | LMNA (0.65) | LMNAMAPTMAPK14MAPK10GCGR | |
| SCHEMBL26548404 | 0.86 | MAPK14 (0.53) | LMNAMAPTMAPK14MAPK10GCGR | |
| SCHEMBL26547982 | 0.86 | MAPK14 (0.53) | LMNAMAPTMAPK14MAPK10GCGR | |
| SCHEMBL26548589 | 0.84 | MAPK14 (0.52) | LMNAMAPTMAPK14MAPK10GCGR | |
| SCHEMBL10000032 | 0.84 | MAPT (0.92) | LMNAMAPTGCGRKIF11KDM4E | |
| SCHEMBL135626 | 0.84 | MAPT (0.92) | LMNAMAPTGCGRKIF11KDM4E | |
| SCHEMBL6337863 | 0.83 | MAPK14 (0.60) | MAPK14MAPK10GCGRMAPK13MAPK12 | |
| SCHEMBL9208657 | 0.82 | LTA4H (0.52) | LMNAMAPTMAPK14MAPK10GCGR | |
| SCHEMBL18770326 | 0.81 | CYP17A1 (0.68) | MAPK14GCGR | |
| SCHEMBL28802099 | 0.81 | KDM4E (0.50) | MAPK14MAPK10GCGRKDM4EAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358550-B | Histone deacetylase inhibitors | 卡鲁斯治疗有限公司 | 2018-04-06 | — | — | CN | claimed |
| CN-106450453-A | Lithium ion battery electrolyte and lithium ion battery containing same | 广州天赐高新材料股份有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-110225912-A | GSK-3 inhibitor | 百时美施贵宝公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-108348523-A | Compositions comprising PI3K inhibitors and HDAC inhibitors | 卡鲁斯治疗有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-105358550-B | Histone deacetylase inhibitors | 卡鲁斯治疗有限公司 | 2018-04-06 | — | — | CN | disclosed |
| CN-104203928-B | Triazineon compounds and T-shaped calcium channel blocker | 日产化学工业株式会社 | 2017-06-06 | — | — | CN | disclosed |
| CN-106450453-A | Lithium ion battery electrolyte and lithium ion battery containing same | 广州天赐高新材料股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2393809-B1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-04 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-1286978-A1 | CYCLOHEXYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087866-A1 | CYCLOHEXYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| US-6090812-A | THERAPY FOR PSYCHOLOGICAL, CENTRAL NERVOUS SYSTEM DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-07-18 | — | — | US | disclosed |
| EP-0908458-A1 | Substituted pyridylmethylpiperazine and -piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | LMNA 714/4885MAPT 2612/4885MAPK14 741/4885 |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | CNR2, CNR1, HRH2 | LMNA 658/4885MAPT 2676/4885MAPK14 979/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | LMNA 1856/4885MAPT 1671/4885MAPK14 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.